Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions

Robert I. Parker, Edwin N. Forman, Kathleen F. Krumm, Mary Jane Abeel, Horace F. Martin

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Serum methotrexate (MTX) levels were measured in 12 children (ages 2-18 years) who received a total of 56 24-h infusions of intermediate-dose methotrexate (500 mg/m2) at 1- to 3-week intervals. Mean peak serum MTX concentration Vi h following a bolus of 167 mg/m2 MTX QA total dose) was 25.9 × 10-6 M, mean plateau serum MTX concentration was 7 × 10-6 M (over 8-24 h), and mean MTX clearance was 74 ml/min/m2. No significant changes in these values were noted with increasing number of infusions, suggesting that no metabolic adaptation occurred in the manner in which the body handled the MTX when it was given repeatedly in this fashion. However, adolescent patients (≥15 years) demonstrated a trend toward increased MTX clearance and decreased serum MTX concentration with ≥5 infusions. In general, toxicity was minimal and did not increase with an increasing number of infusions. Significant toxicity was found only in adolescent patients, in spite of no documented difference in either MTX serum concentrations or clearance rates between adolescent and préadolescent patients.

Original languageEnglish
Pages (from-to)393-399
Number of pages7
JournalTherapeutic Drug Monitoring
Issue number4
StatePublished - Dec 1986
Externally publishedYes


  • Methotrexate
  • Pharmacokinetics
  • Toxicity


Dive into the research topics of 'Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions'. Together they form a unique fingerprint.

Cite this